0 0 0 0.00160042678047485 -0.00466791144305159 -0.00466791144305159 -0.00346759135769545 -0.00360096025606823
Sign Up Today X
Thanks for submitting the form.
Stockreport

Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

Hologic, Inc. (HOLX)  More Company Research Source: Business Wire
Last hologic, inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.hologic.com
Expanded FDA approval across multiple cervical cancer screening modalities supports clinical flexibility and provider choice MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus (HPV) test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126336815/en/Screening for cervical cancer is critically important to women’s health. In the United States, it is estimated that in 2026, approximately 13,490 new cases of invasive cervical cancer will be diagnosed, and about 4,200 women will die from the disease.1 However, many of these deaths are preventable with regular screening and appropriate follow-up on abnormal results. Timely follow-up is essential fo [Read more]
IMPACT SNAPSHOT EVENT TIME: HOLX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
HOLX alerts
from News Quantified
HOLX
NEWS
HOLX
Earnings
HOLX
Analyst Actions
HOLX
SEC Filings
Stockreport

Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

Hologic, Inc.  (HOLX) 
More Company Research Source: Business Wire
Last hologic, inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.hologic.com
Expanded FDA approval across multiple cervical cancer screening modalities supports clinical flexibility and provider choice MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus (HPV) test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126336815/en/Screening for cervical cancer is critically important to women’s health. In the United States, it is estimated that in 2026, approximately 13,490 new cases of invasive cervical cancer will be diagnosed, and about 4,200 women will die from the disease.1 However, many of these deaths are preventable with regular screening and appropriate follow-up on abnormal results. Timely follow-up is essential fo [Read more]
IMPACT SNAPSHOT
EVENT TIME:
HOLX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS